Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression

Simple item page
dc.contributor.authorLin, HQen_AU
dc.contributor.authorKatsifis, Aen_AU
dc.contributor.authorMeriaty, Hen_AU
dc.date.accessioned2011-03-18T02:45:01Zen_AU
dc.date.available2011-03-18T02:45:01Zen_AU
dc.date.issued2010-12-01en_AU
dc.date.statistics2010-12-01en_AU
dc.description.abstractAim: This study was conducted to explore the relationship between different treatment-modulated EGFR expression and gefitinib sensitivity. Materials and Methods: Gefitinib-sensitive (A431) and -resistant (A375, MALME-3M, and SK-MEL 5) tumour cell lines were treated with epidermal growth factor (EGF), gefitinib or radiation in vitro, and EGFR expression levels were measured by using ELISA. Results: EGF, and gefitinib treatment resulted in significantly higher levels of total and/or phosphorylated EGFR in sensitive than in resistant tumours and this was associated with gefitinib IC50. In contrast, radiation-modulated EGFR expression, both total and phosphorylated, did not correlate with the efficacy of gefitinib. Stimulation of proliferation by EGF was significantly stronger in A431 than in the other three lines, indicating sensitive tumours were more EGFR-dependent than resistant tumours for cell proliferation. Conclusion: These findings imply a potential role of EGF- and gefitinib-modulated EGFR expression in predicting gefitinib sensitivity. © 2010, International Institute of Anticancer Researchen_AU
dc.identifier.citationLin, H. Q., Katsifis, A., & Meriaty, H. (2010). Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression. Anticancer Research, 30(12), 4899-4905. Retrieved from http://ar.iiarjournals.org/content/30/12/4899.full.pdfen_AU
dc.identifier.govdoc3320en_AU
dc.identifier.issn0250-7005en_AU
dc.identifier.issue12en_AU
dc.identifier.journaltitleAnticancer Researchen_AU
dc.identifier.pagination4899-4905en_AU
dc.identifier.urihttp://ar.iiarjournals.org/content/30/12/4899.full.pdf+htmlen_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/3147en_AU
dc.identifier.volume30en_AU
dc.language.isoenen_AU
dc.publisherInternational Institute of Anticancer Researchen_AU
dc.subjectNeoplasmsen_AU
dc.subjectGrowth factorsen_AU
dc.subjectEnzyme immunoassayen_AU
dc.subjectCell proliferationen_AU
dc.subjectPhosphorylationen_AU
dc.subjectSensitivityen_AU
dc.titleTumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expressionen_AU
dc.typeJournal Articleen_AU
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4899.full.pdf
Size:
186.83 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles